Guggenheim Reiterates Buy Rating on Cabaletta Bio Inc. (CABA) Jan 27, 2026 07:09AM
Cabaletta Bio (CABA) Reiterated at Overweight by Cantor Fitzgerald Jan 16, 2026 07:10AM
Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy Jan 12, 2026 08:10AM
FDA clears Cabaletta Bio's rese-cel for automated manufacturing platform Jan 12, 2026 07:31AM
Cabaletta Bio, Inc. (CABA) Tops Q3 EPS by 3c Nov 10, 2025 07:42AM


Oct 28, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
Oct 10, 2025 06:45AM Cantor Fitzgerald Reiterates Overweight Rating on Cabaletta Bio Inc. (CABA)
Oct 10, 2025 06:37AM Increasing unusual call option volume: CABA LNC TD RVPH GDRX GGAL TE CODI WWR
Oct 10, 2025 05:30AM Jefferies Resumes Cabaletta Bio Inc. (CABA) at Buy
Sep 24, 2025 06:46AM Cantor Fitzgerald Reiterates Overweight Rating on Cabaletta Bio Inc. (CABA)
Aug 14, 2025 04:29PM Cabaletta Bio Inc. (CABA) PT Lowered to $10 at Citi
Aug 8, 2025 08:33AM Cabaletta Bio Inc. (CABA) PT Lowered to $15 at Guggenheim
Aug 7, 2025 04:52PM Cabaletta Bio Inc. (CABA) PT Lowered to $14 at Jefferies
Jun 27, 2025 11:31AM FDA removing REMS from several CAR-T cell therapies positive for these 3 stocks - William Blair
Jun 13, 2025 07:03AM Cantor Fitzgerald Reiterates Overweight Rating on Cabaletta Bio Inc. (CABA)
Jun 12, 2025 08:13AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
Jun 11, 2025 09:56AM Cabaletta Bio (CABA) Prices Share Offering at $2/sh
Jun 11, 2025 06:15AM Cabaletta Bio (CABA) Announces Proposed Share Offering
Jun 11, 2025 06:01AM Cabaletta Bio (CABA) Announces New Rese-cel Safety and Efficacy Data
Apr 1, 2025 09:04AM Cabaletta Bio Inc. (CABA) PT Lowered to $7 at UBS
Mar 31, 2025 01:11PM Cabaletta Bio Inc. (CABA) PT Lowered to $13 at Stifel
Feb 18, 2025 07:03AM Cabaletta Bio (CABA) Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Jan 17, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
Nov 19, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
Nov 18, 2024 07:00AM Cabaletta Bio (CABA) Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
Nov 14, 2024 01:47PM Guggenheim Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
Oct 10, 2024 03:51AM UBS Starts Cabaletta Bio Inc. (CABA) at Buy
Sep 17, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
Aug 16, 2024 05:31AM Stifel Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)
Aug 8, 2024 09:25AM Cabaletta Bio, Inc. (CABA) Misses Q2 EPS by 1c
Jun 17, 2024 05:29AM Citi Reiterates Buy Rating on Cabaletta Bio Inc. (CABA)